Eli Lilly and Company (LLY)

Eli Lilly is the fastest-growing pharmaceutical company in the world, driven by two blockbuster GLP-1 drugs: Mounjaro (tirzepatide, for type 2 diabetes) and Zepbound (tirzepatide, for obesity). These drugs act on both GIP and GLP-1 receptors simultaneously — a dual mechanism that delivers superior weight loss (15-22%) compared to semaglutide-based drugs. Q4 2025 worldwide revenue hit $19.3 billion, up 43% year-over-year. Lilly guided 2026 full-year revenue to $80–83 billion, implying roughly 30%+ growth from 2025.

Lilly is deploying AI across its drug discovery and clinical trial pipeline to compress development timelines. The company's Mounjaro and Zepbound franchise is the most commercially successful drug launch in pharmaceutical history by revenue trajectory, and the pipeline behind it is equally deep: orforglipron (oral GLP-1 tablet), retatrutide (triple receptor agonist), and AI-driven targets in Alzheimer's, oncology, and immunology. The addressable market for obesity drugs alone is estimated at $100B+ annually — and Lilly is positioned as the dominant supplier.